Glass House Brands (GLAS) Net Income towards Common Stockholders (2020 - 2026)

Glass House Brands' (GLAS) quarterly Net Income towards Common Stockholders came in at -$17.0 million in Q1 2026, down 9.72% on a QoQ basis from -$15.5 million in Q4 2025.

Glass House Brands (GLAS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$17.0 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to -$17.0 million in Q1 2026; TTM through Mar 2026 was -$36.0 million, a 460.39% decrease from a year earlier, with the FY2025 full-year figure at -$29.0 million, down 4115.53% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$17.0 million, down from -$15.5 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for GLAS reached as high as $33.2 million in Q4 2023 and fell as low as -$20.4 million in Q1 2022.
  • Historically, Net Income towards Common Stockholders has averaged $3.2 million across 5 years, with a median of $7.5 million in 2023.
  • Across the five-year window, Net Income towards Common Stockholders surged 219.88% in 2023 and tumbled 63.8% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at $16.5 million in 2022, then surged by 101.02% to $33.2 million in 2023, then slumped by 69.86% to $10.0 million in 2024, then tumbled by 255.06% to -$15.5 million in 2025, then fell by 9.72% to -$17.0 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$17.0 million in Q1 2026, -$15.5 million in Q4 2025, and -$12.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn -17.01 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.01 Mn
Dec 31, 2025 -15.50 Mn
Sep 30, 2025 -12.19 Mn
Jun 30, 2025 8.67 Mn
Jun 30, 2024 10.00 Mn
Mar 31, 2024 8.86 Mn
Dec 31, 2023 33.17 Mn
Sep 30, 2023 6.28 Mn
Jun 30, 2023 3.22 Mn
Mar 31, 2023 24.47 Mn
Dec 31, 2022 16.50 Mn
Sep 30, 2022 15.17 Mn
Jun 30, 2022 -17.03 Mn
Mar 31, 2022 -20.41 Mn
Dec 31, 2021 -18.99 Mn
Sep 30, 2021 -6,955.68 Bn
Jun 30, 2021 -13,606.55 Bn
Mar 31, 2021 -13.15 Mn
Dec 31, 2020 -23,713.35 Bn
Sep 30, 2020 -1.15 Mn